Oncolys BioPharma (TYO:4588) said Phase I trial results showed oncolytic adenoviral immunotherapy, Telomelysin (OBP-301), can be safely administered with chemoradiation in the treatment of advanced esophageal or gastro-esophageal cancer.
The results also showed a high clinical complete response rate in patients with locally advanced tumors ineligible for surgery, the filing said.
Oncolys BioPharma's shares gained over 3% at market close.
Price (JPY): $591.00, Change: $+19, Percent Change: +3.32%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.